Beryl Capital Management’s Starling Oncology STLN Stock Holding History

Beryl Capital Management’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-197,924	Closed	-$1.96M	–	391
2021 Q3	$1.96M	Hold	197,924	–	–	0.14%	163
2021 Q2	$1.97M	Hold	197,924	–	–	0.18%	132
2021 Q1	$1.97M	Buy	+197,924	New	+$2.11M	0.25%	100

Other funds holding STLN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

PGM

Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return

AGM

Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return

SCM

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Beryl Capital Management's STLN Position: Q4 2021 in Review

Beryl Capital Management sold out of Starling Oncology (STLN) in Q4 2021, closing a stake of 197,924 shares — an estimated $1.96M sold.

Beryl Capital Management first reported a position in STLN in Q1 2021 and held it in 3 quarters. The position peaked at $1.97M in Q1 2021. 21 funds tracked by Wall St. Rank hold STLN as of Q4 2021.

Beryl Capital Management reported no remaining Starling Oncology position as of Q4 2021 after selling out during the quarter.
Beryl Capital Management sold 197,924 Starling Oncology shares in Q4 2021, an estimated $1.96M.
Beryl Capital Management first reported a position in Starling Oncology in Q1 2021 and held it in 3 quarters.
Beryl Capital Management's Starling Oncology position peaked at $1.97M in Q1 2021.
21 funds tracked by Wall St. Rank held Starling Oncology as of Q4 2021.

Based on Beryl Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.